MA56883B1 - Dérivés de 2-hydroxycycloalcane-1-carbamoyle - Google Patents

Dérivés de 2-hydroxycycloalcane-1-carbamoyle

Info

Publication number
MA56883B1
MA56883B1 MA56883A MA56883A MA56883B1 MA 56883 B1 MA56883 B1 MA 56883B1 MA 56883 A MA56883 A MA 56883A MA 56883 A MA56883 A MA 56883A MA 56883 B1 MA56883 B1 MA 56883B1
Authority
MA
Morocco
Prior art keywords
hydroxycycloalkane
carbamoyl derivatives
compounds
formula
carbamoyl
Prior art date
Application number
MA56883A
Other languages
English (en)
Inventor
Martin Bolli
Cornelia Zumbrunn
John Gatfield
Corinna Grisostomi
Lubos Remen
Christoph SAGER
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MA56883B1 publication Critical patent/MA56883B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des composés de formule (I) dans laquelle Ar1, Ar2, L, n, et R1 sont tels que décrits dans la description, leur préparation, leurs sels pharmaceutiquement acceptables, et leur utilisation en tant que produits pharmaceutiques, des compositions pharmaceutiques contenant un ou plusieurs composés de formule (I), et en particulier leur utilisation en tant qu'inhibiteurs de galectine-3.
MA56883A 2019-08-15 2020-08-14 Dérivés de 2-hydroxycycloalcane-1-carbamoyle MA56883B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2019071921 2019-08-15
EP20767476.3A EP4013751B1 (fr) 2019-08-15 2020-08-14 Dérivés de 2-hydroxycycloalcane-1-carbamoyle
PCT/EP2020/072865 WO2021028570A1 (fr) 2019-08-15 2020-08-14 Dérivés de 2-hydroxycycloalcane-1-carbamoyle

Publications (1)

Publication Number Publication Date
MA56883B1 true MA56883B1 (fr) 2025-04-30

Family

ID=72355943

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56883A MA56883B1 (fr) 2019-08-15 2020-08-14 Dérivés de 2-hydroxycycloalcane-1-carbamoyle

Country Status (20)

Country Link
US (1) US12291519B2 (fr)
EP (1) EP4013751B1 (fr)
JP (1) JP7604457B2 (fr)
KR (1) KR102832308B1 (fr)
CN (1) CN114269737A (fr)
AU (1) AU2020329609B2 (fr)
BR (1) BR112021026829A2 (fr)
CA (1) CA3147454A1 (fr)
ES (1) ES3015725T3 (fr)
HR (1) HRP20250372T1 (fr)
HU (1) HUE070924T2 (fr)
IL (1) IL289197B2 (fr)
MA (1) MA56883B1 (fr)
MX (1) MX2022001789A (fr)
PH (1) PH12022550338A1 (fr)
PL (1) PL4013751T3 (fr)
RS (1) RS66695B1 (fr)
TW (1) TWI864071B (fr)
UA (1) UA128909C2 (fr)
WO (1) WO2021028570A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2974680T3 (es) 2019-08-09 2024-07-01 Idorsia Pharmaceuticals Ltd Derivados de (2-acetamidil)tio-beta-D-galactopiranósidos
US12404295B2 (en) 2019-08-09 2025-09-02 Idorsia Pharmaceuticals Ltd (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives
PH12022550436A1 (en) 2019-08-29 2022-12-19 Idorsia Pharmaceuticals Ltd Alpha-d-galactopyranoside derivatives
JP2023508363A (ja) * 2019-12-24 2023-03-02 グリコミメティクス， インコーポレイテッド ガレクチン－３阻害性ｃ－グリコシドケトン、エーテル、およびアルコール
AU2021356076A1 (en) 2020-10-06 2023-06-08 Idorsia Pharmaceuticals Ltd Spiro derivatives of alpha-d-galactopyranosides
IL302421A (en) 2020-11-02 2023-06-01 Idorsia Pharmaceuticals Ltd Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives
JP7844491B2 (ja) * 2021-02-09 2026-04-13 イドルシア・ファーマシューティカルズ・リミテッド ヒドロキシヘテロシクロアルカン－カルバモイル誘導体
EP4301748B1 (fr) 2021-03-03 2025-05-07 Idorsia Pharmaceuticals Ltd Dérivés d'alpha-d-galactopyranoside substitués par triazolyl-méthyle
WO2022189459A2 (fr) * 2021-03-10 2022-09-15 Galecto Biotech Ab Nouvel inhibiteur de galectines à base de galactoside
EP4337657A1 (fr) * 2021-05-14 2024-03-20 GlycoMimetics, Inc. C-glycosides inhibiteurs de galectine-3
WO2022250976A1 (fr) * 2021-05-28 2022-12-01 Glycomimetics, Inc. Oximes de c-glycoside inhibant la galectine 3

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100172D0 (sv) 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
SE0401301D0 (sv) * 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
ES2698101T3 (es) 2012-10-10 2019-01-31 Galectin Therapeutics Inc Compuestos de carbohidrato con restos de galactosa para el tratamiento de la nefropatía diabética y trastornos asociados
EP2914269B1 (fr) 2012-10-31 2020-07-29 Galecto Biotech AB Galactoside inhibiteur du galectine-3 et son utilisation pour traiter la fibrose pulmonaire
WO2014078655A1 (fr) 2012-11-15 2014-05-22 Tufts University Méthodes, compositions et kits de traitement, de modulation ou de prévention de l'angiogenèse ou de la fibrose oculaire chez un sujet utilisant un inhibiteur de galectine
EP3250581B1 (fr) * 2015-01-30 2021-01-20 Galecto Biotech AB Inhibiteurs de alpha-d-galactoside de galectines
KR20220129667A (ko) 2015-07-06 2022-09-23 길리애드 사이언시즈, 인코포레이티드 Cot 조정제 및 그의 사용 방법
US10889610B2 (en) 2016-07-12 2021-01-12 Galecto Biotech Ab Alpha-D-galactoside inhibitors of galectins
AU2018265571B2 (en) * 2017-05-12 2022-09-29 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof
CN111032670A (zh) * 2017-05-12 2020-04-17 卡莱克汀科学有限责任公司 用于治疗系统性胰岛素抗性病症的化合物及其用途
WO2019067702A1 (fr) * 2017-09-27 2019-04-04 Bristol-Myers Squibb Company Inhibiteurs à petites molécules de galectine-3
US11072626B2 (en) 2017-10-11 2021-07-27 Bristol-Myers Squibb Company Small molecule inhibitors of Galectin-3
JP2021501180A (ja) 2017-10-31 2021-01-14 ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＧａｌｅｃｔｉｎ Ｓｃｉｅｎｃｅｓ， ＬＬＣ 全身インスリン抵抗性障害の治療のためのセレノガラクトシド化合物およびその使用
CA3114055A1 (fr) 2018-10-15 2020-04-23 Galecto Biotech Ab Promedicament de galactoside inhibiteur de galectines
JP2022508720A (ja) 2018-10-15 2022-01-19 ガレクト バイオテック エービー ガレクチンのガラクトシド阻害剤
CA3116515A1 (fr) 2018-11-21 2020-05-28 Galecto Biotech Ab Inhibiteurs alpha-d-galactoside de galectines
WO2020210308A1 (fr) 2019-04-10 2020-10-15 Bristol-Myers Squibb Company Inhibiteurs à petites molécules de galectine -3
US12441754B2 (en) 2019-07-03 2025-10-14 Galecto Biotech Ab Galactoside inhibitor of galectins
US12441755B2 (en) 2019-07-05 2025-10-14 Galecto Biotech Ab Galactoside inhibitor of galectins
ES2974680T3 (es) 2019-08-09 2024-07-01 Idorsia Pharmaceuticals Ltd Derivados de (2-acetamidil)tio-beta-D-galactopiranósidos
US12404295B2 (en) 2019-08-09 2025-09-02 Idorsia Pharmaceuticals Ltd (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives
PH12022550436A1 (en) 2019-08-29 2022-12-19 Idorsia Pharmaceuticals Ltd Alpha-d-galactopyranoside derivatives
AU2021356076A1 (en) 2020-10-06 2023-06-08 Idorsia Pharmaceuticals Ltd Spiro derivatives of alpha-d-galactopyranosides
IL302421A (en) 2020-11-02 2023-06-01 Idorsia Pharmaceuticals Ltd Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives
JP7844491B2 (ja) 2021-02-09 2026-04-13 イドルシア・ファーマシューティカルズ・リミテッド ヒドロキシヘテロシクロアルカン－カルバモイル誘導体
EP4301748B1 (fr) 2021-03-03 2025-05-07 Idorsia Pharmaceuticals Ltd Dérivés d'alpha-d-galactopyranoside substitués par triazolyl-méthyle

Also Published As

Publication number Publication date
EP4013751B1 (fr) 2025-01-22
HRP20250372T1 (hr) 2025-06-06
JP7604457B2 (ja) 2024-12-23
TW202115039A (zh) 2021-04-16
KR20220047585A (ko) 2022-04-18
HUE070924T2 (hu) 2025-07-28
IL289197A (en) 2022-02-01
UA128909C2 (uk) 2024-11-20
RS66695B1 (sr) 2025-05-30
JP2022544248A (ja) 2022-10-17
PH12022550338A1 (en) 2023-02-06
PL4013751T3 (pl) 2025-05-19
IL289197B1 (en) 2025-10-01
BR112021026829A2 (pt) 2022-02-22
AU2020329609A1 (en) 2022-02-24
KR102832308B1 (ko) 2025-07-10
ES3015725T3 (en) 2025-05-07
AU2020329609B2 (en) 2025-10-02
CN114269737A (zh) 2022-04-01
IL289197B2 (en) 2026-02-01
EP4013751A1 (fr) 2022-06-22
CA3147454A1 (fr) 2021-02-18
US12291519B2 (en) 2025-05-06
US20220324847A1 (en) 2022-10-13
TWI864071B (zh) 2024-12-01
MX2022001789A (es) 2022-03-11
WO2021028570A1 (fr) 2021-02-18
EP4013751C0 (fr) 2025-01-22

Similar Documents

Publication Publication Date Title
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA67365B1 (fr) Dérivés de benzisoxazole sulfonamide
MA57000B1 (fr) Dérivés d'alpha-d-galactopyranoside
MA55046B1 (fr) Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2
MA27560A1 (fr) Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation
MA27559A1 (fr) Nouveaux derives de fluorglycoside aromatiques, produits pharmaceutiques contenant ces composes et leur utilisation
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA52360B1 (fr) Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu'inhibiteurs de kinases dépendantes des cyclines
MA29926B1 (fr) Derives de pyrazine
TNSN07022A1 (fr) Derives de pyridine
MA49127B1 (fr) Dérivés d'indole n-substitués
MA45223A (fr) Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenant
TN2009000450A1 (fr) Derives de pyridine
MA43639B1 (fr) Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA31754B1 (fr) Cis-imidazolines chirales
MA38138A1 (fr) Dérivés inédits de quinolone
TNSN07476A1 (fr) Derives de n-(pyridine -2- yl) - sulfonamide
MA63589B1 (fr) Dérivés d'alpha-d-galactopyranoside substitués par triazolyl-méthyle
MA45222A (fr) Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA30142B1 (fr) Agonistes du recepteur de neuropeptide-2
TNSN08139A1 (fr) Composes therapeutiques
MA27093A1 (fr) Derives de sulfonamides, leur preparation et leur application comme medicaments.
PH12022550338A1 (en) 2-hydroxycycloalkane-1-carbamoyl derivatives
MA30487B1 (fr) Nouveaux composes heterocycliques
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2